The process of bringing a new drug from research and development to market is a long and complex journey.

Tallac Therapeutics Unveils Novel Preclinical Findings for TAC-001 Paired with Oncology Vaccines at AACR's 2024 Yearly Convention.

April 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

At the AACR 2024, Crescendo Biologics showcased early-stage findings for its primary investigational drug, CB307, while also revealing CB699, their inaugural dual-functioning immune cell attractor.

The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.

4.8-4.14 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

April 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Monopar Therapeutics Launches Phase 1 Trial for Novel MNPR-101-Zr Diagnostic Molecule.

The article presents the clinical trial outcomes that failed globally in March.

Nurix Therapeutics Announces Initial Clinical Signs of Brain Activity for NX-5948, an Orally Administered Compound That Crosses Blood-Brain Barrier and Targets BTK for Treating B Cell Cancers.

The article presents the clinical trial outcomes that failed globally in February.

Foghorn Therapeutics Unveils Novel Early-Stage Research Findings for Unique BRM Targeted Inhibitor FHD-909 and Distinct CBP & EP300 Degrader Initiatives in Cancer Treatment.